Plastics Rigid Box Manufacturers

How much will the macroeconomic downturn affect the company? What measures should the company take to deal with it?

Dear investor, the macroeconomic downturn is both a challenge and an opportunity for us. In the pharmaceutical manufacturing industry where HySum is engaged, the demand of downstream pharmaceutical companies for packaging materials is growing steadily. During the reporting period, we achieved operating income of RMB 480.1352 million, an increase by 11.93% year-on-year; the net profit attributable to shareholders of the listed company was RMB 55.021 million, 6.14% down year-on-year. We are full of confidence in our future growth. We will seek technological innovation & breakthrough all the time to create commanding heights of product competition; actively adapt production capacity and guarantee production safety; deepen the marketing mechanism and actively enhance market share; improve our management efficiency and governance system. Adhering to its "four-wheel drive" development strategy, HySum is intensively engaged in pharmaceutical packaging materials, and actively builds up presence in new consumption, new energy and recyclable composites, etc., which provides new impetus for our sustainable development. Thank you for your attention.

Do you have any new project planned in the near future?

Dear investor, we are actively promoting production capacity enhancement, and carrying out plant construction, equipment purchase, market buildup, etc., for the new projects regarding directional add-issuance, convertible bonds, etc. In the sector of pharmaceutical packaging, we are enhancing market presence of traditional products and making active efforts for new pharmaceutical packaging projects for high-performance bottles, precision drug delivery devices, reagent packaging, etc. Thank you for your attention.

How much has the pandemic affected HySum?

Dear investor, the logistics & transport, marketing promotion, production & construction, etc., were interrupted from time to time due to the epidemic repetition this year. Under the leadership of our Management, however, all those who worked for HySum weathered the difficulties together to have achieved operating income of RMB 480.1352 million, an increase by 11.93% year-on-year; the net profit attributable to shareholders of the listed company was RMB 55.021 million, 6.14% down year-on-year. Thank you for your attention.

Please describe the production capacity of Phase I of the Nanxun Project and how much profit it can bring to HySum.

Dear investor, the total building area of "Phase I of the Nanxun Project" is 120,000 square meters. HySum's production capacity occupies about 50,000 square meters, including 5,000 square meters for the 3,700 t high-barrier composite and 45,000 square meters for the convertible bond project; approx. 70,000 square meters are for capacity relocation of Shanghai Jiucheng, a shareholding company. It is expected that the related production capacity will lay a solid foundation for the sustainable development of HySum. Thank you for your attention.

What is the core competitiveness of HySum? Who are the competitors? How is the competition in the industry?

Dear investor. HySum has established its dominant position in the field of novel pharmaceutical packaging on the strength of its continuous technology research and development, abundant customer resources, cutting-edge production equipment, perfect management certification system, excellent team management and other strengths through years of development. HySum makes progress together with business competitors to promote the benign development of its industry. Thank you for your attention.